Guardion Health Sciences, Inc. (GHSI): Price and Financial Metrics
GET POWR RATINGS... FREE!
GHSI POWR Grades
- Value is the dimension where GHSI ranks best; there it ranks ahead of 56.64% of US stocks.
- The strongest trend for GHSI is in Growth, which has been heading down over the past 122 days.
- GHSI ranks lowest in Stability; there it ranks in the 0th percentile.
GHSI Stock Summary
- Guardion Health Sciences Inc's stock had its IPO on April 5, 2019, making it an older stock than only 4.62% of US equities in our set.
- Of note is the ratio of Guardion Health Sciences Inc's sales and general administrative expense to its total operating expenses; 98.31% of US stocks have a lower such ratio.
- In terms of volatility of its share price, GHSI is more volatile than 99.37% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Guardion Health Sciences Inc are EZPW, SVVC, IMRN, HLG, and MGIC.
- Visit GHSI's SEC page to see the company's official filings. To visit the company's web site, go to www.guardionhealth.com.
GHSI Stock Price Chart Interactive Chart >
GHSI Price/Volume Stats
|Current price||$1.58||52-week high||$8.40|
|Prev. close||$1.47||52-week low||$0.99|
|Day high||$1.61||Avg. volume||3,485,279|
|50-day MA||$2.09||Dividend yield||N/A|
|200-day MA||$2.35||Market Cap||38.59M|
Guardion Health Sciences, Inc. (GHSI) Company Bio
Guardion Health Sciences, Inc. provides health care services. It offers, Lumega-Z a medical food formulated to replenish and restore the macular protective pigment. The firm also develops medical devices that measures macular pigment density. The company was founded by Michael Favish in 2009 and is headquartered in San Diego, CA.
GHSI Latest News Stream
|Loading, please wait...|
GHSI Latest Social Stream
View Full GHSI Social Stream
Latest GHSI News From Around the Web
Below are the latest news stories about Guardion Health Sciences Inc that investors may wish to consider to help them evaluate GHSI as an investment opportunity.
Guardion Health Sciences Announces Financial Results for the Three Months and Year Ended December 31, 2020
Company Provides Corporate Update and Overview of Growth PlansSAN DIEGO, March 26, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops science-based, clinically supported nutritional supplements, medical foods, and diagnostic products, announced financial results for the three months and year ended December 31, 2020. Effective March 1, 2021, the Company amended its Certificate of Incorporation to effectuate a 1-for-6 reverse split of its outstanding common stock. Accordingly, all share and per share amounts included herein have been retroactively adjusted to reflect the reverse stock split for all periods presented. Financial highlights for the year ended December 31, 2020 includ...
Shares of Guardion Health Sciences Inc. undefined tumbled 24.0% in premarket trading Friday, after the medical foods company focused on ocular health said it…
Guardion Health Sciences Announces 1-for-6 Reverse Stock Split Effective Pre-Market Opening on Monday, March 1, 2021
Recent at-the-market financings and warrant exercises have netted a combined $37.2 million in 2021, providing an effective cash runway for program execution and acquisition strategy implementation SAN DIEGO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods, nutraceuticals and medical devices, with a focus in the ocular health marketplace, today announced it will effect a 1-for-6 reverse split of its common stock effective as of 6:00 a.m. Eastern Time on Monday, March 1, 2021. Commencing with the opening of trading on the Nasdaq Capital Market on Monday, March 1, 2021, the Company’s common stock will trade on a post-split basis unde...
The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics ...
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASD...
GHSI Price Returns